Cutaneous leishmaniasis is considered to be one of the most neglected and serious parasitic infectious skin diseases in many developing countries. We have assessed the design and reporting of randomized, controlled trials evaluating treatments included in 2 Cochrane systematic reviews on cutaneous leishmaniasis. The analysis of the methodological quality identified some potential bias that can make it difficult to determine whether truly effective therapies exist for this disease. We found important weaknesses in the adequacy and transparency of randomization, loss of participants, causative Leishmania species, outcome measures, and follow-up times. Given these distorting effects on the evidence base, we propose guidelines for authors who wish to conduct clinical trials aimed at the development of effective therapies in cutaneous leishmaniasis. The recommendations in this report will hopefully deserve the attention of the World Health Organization and assist in the planning and prioritization of global strategies for improving the interpretation and replication of clinical research on cutaneous leishmaniasis.
and disability in low-income countries [4] . However, to improve existing control of disease, evidence for the effectiveness of different treatment strategies is needed.
Many different treatments for CL have been described. Pentavalent antimonial drugs are the main first-line therapeutic agents worldwide, despite their toxicity. Although other drugs and treatment modalities have been used with varying success, the present and future strategies for the control of CL are centered in new treatments and their availability in rural and poorer areas [5] . Therefore, future trials of different anti-Leishmania drugs, compared with placebo, in self-healing forms of leishmaniasis or antimony-alternative treatments, compared with traditional first-line antimonials, in the complicated forms need to be designed in such a way to guarantee the discernment of efficacy between treatments.
The rise of evidence-based medicine has highlighted the use of systematic reviews of the best evidence as fundamental tools for health care. The quality of randomized clinical trials (RCTs) is essential to determine what therapeutic interventions work and are safe in people with CL. Special attention must be drawn to the design, conduct, analysis, clinical relevance, and reporting of the trials; otherwise, the conclusions derived from low quality and biased trials may remain elusive [6] .
DESCRIPTION OF THE SOURCES OF BIAS FROM EXISTING RCTS ON TREATMENTS FOR CL
This article offers some guidelines based on the assessment of the quality of design and reporting of RCTs evaluating treatments for CL from 2 Cochrane systematic reviews on treatments for Old World and American CL (Table 1) [7, 8] .
Selection bias. In RCTs, selection bias refers to the possible differences between baseline characteristics in the groups under comparison. Investigators should devote appropriate resources for allocating interventions to participants on the basis of some chance (random) process and report their methods clearly [9] , avoiding nonrandom methods of allocation. Adequate generation of the randomization sequence takes little effort and enhances scientific accuracy and credibility. However, randomization persists as the leastunderstood feature of trials. All RCTs included in the Cochrane reviews stated or implied that treatment allocation was randomized; however, only 35% (18 of 52) and 33% (13 of 40) of studies in the Old World CL review and American CL review, respectively, clearly stated an adequate randomization method. Proper randomization also rests on adequate allocation concealment, a process that keeps clinicians and participants unaware of upcoming assignments by preventing foreknowledge of the forthcoming allocations. Inadequate allocation concealment leads to either an underestimation or an overestimation of the treatment effect under investigation [103] . Even allocation concealment is an essential step to secure strict implementation of that schedule of random assignments; however, only 12% (6 of 52) of studies in the Old World CL review and 13% (5 of 40) of studies in the American CL review had an adequate reporting of the allocation concealment.
Blinding assessment. In clinical research, blinding is used to eliminate the risk of subjectivity in the assessment [104] . Success of blinding is a fundamental issue in many clinical trials. Forty percent (21 of 52) of RCTs included in the Old World CL review were double blinded. Thirty eight percent (15 of 40) of RCTs included in the American CL review were double blinded. Some interventions might be difficult to blind; however, 25% (13 of 52) and 18% (7 of 40) of studies in the Old World and American CL reviews, respectively, did not address blinding.
Attrition bias. Attrition bias is caused by a selective loss of participants (eg, withdrawals, dropouts, and protocol deviations) from the population that was initially selected. This bias can produce a deviation of the measure of the effect of intervention from its true value because of different rates of loss of participants between the intervention and the comparison group. To avoid attrition bias, an analysis assuming that missing data represent treatment failures is recommended [105] .
Losses to follow-up were comparable in the Old World and American CL review, although in both cases, the majority of studies only assessed participants who completed treatment. Losses to follow-up occurred in 69% (36 of 52) of studies in the Old World CL review, and 83% (30 of 36) of studies did not carry out original assigned group analyses. Losses to followup occurred in 63% (25 of 40) of the studies in the American CL review, and 76% (19 of 25) of studies did not perform original group analyses.
A further important step in the study design is the calculation of the sample size; otherwise, the outcomes from studies with inadequate sample sizes are likely to be imprecise or provide false negatives. Only 25% (13 of 52) and 18% (7 of 40) of RCTs in the Old World and American CL review, respectively, calculated the sample size.
Overall, we found 3 trials in the Old World CL [12, 28, 29] and 2 trials in the American CL review [89, 99] that fulfilled randomization, allocation concealment, blinding, and group analyses adequately. In both Cochrane systematic reviews, additional information about the following 3 key elements of the study question that could influence the quality of the RCT was also analyzed: participants (Table 2 ), interventions (Tables 3 and 4) , and outcomes (Table 5) .
Participants. Most of the RCTs recorded baseline characteristics of participants and defined the inclusion and exclusion criteria. In the American CL review, one-third of the included RCTs recruited male subjects only. None of the included RCTs in either of the reviews reported participants with immunodeficiency, coinfections with human immu- Interventions. Few treatments for Old World and American CL have been well evaluated in RCTs. There was a complete absence of evidence on intramuscular pentamidine and topical amphotericin B in Old World CL, whereas there was no or little evidence for oral (antifungals and antibiotics) and local treatments, such as photodynamic therapy, laser, cryotherapy treatments, or alternative therapies, for American CL. In addition, there have been no trials involving the use of woundhealing management or alternative supportive therapies versus drug interventions for Old World and American CL.
Outcomes. It was not possible to find a general measure to define efficacy of an intervention. This resulted in heterogeneity of the outcome measures, which in turn hampered the possibility of a metaanalysis. The primary outcome for the Cochrane reviews was considered to be the percentage of participants "cured" at 3 months after the end of treatment, defined as the absence of all inflammatory signs (skin edema and/or hardening) and complete scarring or repair of ulcerative lesions [7, 8] . Only one-third of studies in the Old World CL review and over one-half in the American CL review reported this primary outcome. Outcomes were always recorded by physicians, and none of the included studies assessed degree of functional deterioration, quality-of-life, or aesthetic impairment, although some strains may cause extensive skin damage and disfigurement.
GUIDELINES FOR DESIGNING AND REPORTING RCTS ON TREATMENTS FOR CL
For the execution of a properly designed RCT aimed at the development of effective therapies in CL, it is necessary to establish standard clinical trial designs, rigorous peer review in journals, and to enhance the capacity for high quality trials. Given the gaps and potential bias found in the design and reporting of current clinical trials, we propose guidelines for authors who wish to conduct clinical trials on treatments for CL (Table 6 ). There are other valid and desirable reasons for conducting good RCTs on treatments for CL in developing countries because they can help with the development of local capacities and benefit populations with care that would otherwise be difficult to obtain [106, 107] . Investigators need to reinforce ethical practices because there is an impoverished reality of underresourced and understaffed health structures in most countries where CL is endemic [108, 109, 110] .
The Study Question
Participants. Participants in RCT should be able to understand the nature and the purpose of the research and have a chance to have their queries answered. The informed consent process guarantees the free decision of participants on the basis of a good understanding of the information provided. Other treatment alternatives should be part of the information provided to all participants. Once the trial is completed, participants should have access to safe and beneficial therapies in environments where it is very difficult to access the public health services, as well as the results of the research. Inclusion criteria are important to define the cases. Investigators should use parasitology to confirm the presence of lesions in eligible patients by direct smears and/or skin-punch biopsies of the active, infiltrated edge of a representative lesion. It is always important to specify criteria for exclusion, such as patients with multiple or disseminated lesions, pregnancy or potential for pregnancy, breast-feeding, chronic illness or concomitant disease, an immunologically compromised condition, and others.
The main selection biases in RCTs are found in the description of baseline characteristics, which need to be fully detailed to ensure homogeneity and comparability between groups. It is strongly recommended that investigators fully report baseline characteristics on a table describing age, sex, geographic area of residence, history of travel in an endemic area, duration of disease, number and morphology of lesions, sites and severity of lesions, previous treatment received, and past history of liver disease or characteristics such as infiltration, erythema, ulceration, and scaling.
There are several species of Leishmania involved in Old World and American CL. Thus, in CL it is especially relevant to analyze the infective species because it is well known that they respond differently to the same drug. There is also an urgent need for the standardized definition of clinical manifestations in clinical trials. The diagnostic tools for Leishmania identification are not always feasible or reliable, which delays the onset of treatment because of false negative results. Thus, there is a need to improve detection methods to avoid false negative results and to speed up the identification of the parasite at a species level, which will affect the choice and start of treatment.
Interventions. A placebo control group is not always feasible, not only because of the nature of some interventions, especially the systemic ones, which hamper the design of a placebo-controlled trial, but also because of specific situations where a placebo group may go against ethical principles and compromise a participant's well-being. The choice of active control or placebo treatment as the comparator within the context of developing countries must be determined in close consultation with local experts and health authorities and ideally be aligned with locally sustainable health care practice.
Compliance assessment is an important issue in RCTs conducted in developing countries. Compliance should be measured to ensure adherence to treatment and can be assessed using many standardized methods, such as requesting the return of unused medication, counts of remaining capsules/sachets/tablets, or patient interview. When possible, clinical trials could consider hospitalization to ensure compliance. However, the period of time and the best method to measure compliance remain unclear.
Outcome measures. Treatment duration and follow-up times should be clearly defined in the study protocol. Long-term efficacy of intervention and sustainability of responses may be determined with enough extended follow-up of patients after termination of therapy. However, the duration of follow-up may vary depending on the expected time of responses of well-known short-or longacting drugs. The definition of the outcomes needs to be rigorous to make clinical sense and to be reproduced by others. It is preferable to analyze participants rather than lesions because it is more Inclusion criteria: it is important to define the cases and the parasitological confirmation of cutaneous leishmaniasis.
Exclusion criteria may include: previous treatment with anti-Leishmania therapy, any chronic or concomitant disease, pregnancy, potential for pregnancy or breast feeding females, immunodeficiency, coinfections with HIV, or use of immunosuppressants.
Description of baseline characteristics of the participants by group: severity and duration of infection, number, size and site of lesions, age, sex, ethnicity.
+++
Analysis and report of the Leishmania species involved. + Study setting (eg, primary or secondary care, country, number of centers) . +++
Interventions
Adequate description of the intervention (name, trade mark, route of administration, doses and regimen schedule).
+++
Control arm (placebo arm only in limited infective species, Leishmania major, and Leishmania mexicana, but an active control is recommended for other species).
++
Adherence to treatment or compliance should be measurable, measured and reported. +
Outcomes
Adequate follow-up and frequency of data recording. We suggest a minimum time period of 3 months after the end of treatment. Extended times of follow-up may be useful in long-acting interventions and for evaluating recurrence.
++
Standardized definition of cure and measurements scales (especially for combination therapies). + Define primary and secondary outcomes. + Suggested primary outcome: percentage of participants with a complete cure at three months after the end of treatment).
Suggested secondary outcomes: speed of healing (time taken to be 'cured'; recurrence (duration of remission and/or percentage of people with treated lesions that recur within six months, one, two and three years); degree of functional and aesthetic impairment; prevention of scarring; quality of life; adverse effects; change in ability to detect Leishmania by parasitological diagnostic methods (eg, smear, PCR, or culture); emergence of resistance; microbiological or histopathological cure of skin lesions; and development of cell-mediated immunity (ie, positive leishmanin skin test).
Study design
Criteria for adequate generation of randomization sequence: random numbers generated by computer or table of random numbers or other unbiased methods of allocation.
+
Criteria for adequate allocation concealment: participants and investigators enrolling participants cannot foresee assignment (ie, central allocation, including telephone, web-based or pharmacy-controlled randomization; a priori third-party sequentially numbered or coded drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes; or other descriptions that contain convincing elements of concealment).
Blinding (who and how they are blinded). ++ Calculation of the sample size. + Losses to follow-up per arm (when and why) and intention-to-treat analysis (analysis that include the total number of randomized participants, irrespective of what happened subsequently or how the original study authors analyzed the data).
++ Data reporting
Follow CONSORT guidelines (authors, journals, and referees). + NOTE. HIV, human immunodeficiency virus; PCR, polymerase chain reaction. +, none or few described in reviewed RCTs; ++, fairly well described in reviewed RCTs; +++, mostly well described in reviewed RCTs.
clinically relevant to determine the proportion of participants who achieved the stipulated outcome. Outcomes should be reported in all groups to avoid selective bias. Because recurrence occurs frequently after the treatment of CL, outcome measures should be reported at regular intervals to provide documentation of whether a treatment demonstrates a gradual and sustained improvement or, rather, extensive fluctuations over the course of the study.
We recommend the percentage of participants with a complete cure at 3 months after the end of treatment as the primary outcome for RCTs investigating treatments for CL. Reporting of adverse events is necessary in trials and at least some of the following secondary outcomes: degree of functional and aesthetic impairment; prevention of scarring; quality-of-life measured with validated scales; speed of healing (time taken to be "cured"); recurrence (duration of remission and/or percentage of participants with treated lesions that recur within 6 months and 1, 2, and 3 years, depending of the duration of the trial); change in ability to detect Leishmania by parasitological diagnostic methods (eg, smear, polymerase chain reaction, or culture); emergence of resistance (defined as a decrease in the efficacy of a drug against a population of parasites previously susceptible to that compound; the definition assumes that the original susceptibility of the population is known, which is not always the case for Leishmania); microbiological or histopathological cure of skin lesions; and development of cell-mediated immunity (ie, positive leishmanin skin test).
The Study Design
The main analysis of RCTs on treatments for CL should be focused on the primary outcome, which should also form the basis of the general conclusion of the study. Sample size needs to be calculated to ensure sufficient statistical power to appropriately evaluate the primary outcome measure. The fact that sample size, a source of potential imprecision, may lead to bias does not necessarily mean that small studies cannot provide some useful information about drug efficacy. The rationale used for the calculation of sample size should be specified in the study protocol.
Additionally, the statistical analysis should be based on full reporting of the reasons for withdrawal and the stage in which they occurred. Because a large proportion of missing data (ie, withdrawals) will diminish the credibility of a study, the best advice is to minimize the chance of withdrawals at the design stage or during the trial [111] . Secondary and tertiary outcomes may help to support the di-rection and magnitude of the primary outcome. Finally, all outcomes need to be reported with the estimated effect of the intervention and the 95% confidence interval to allow further meta-analysis (ie, the mean and the standard deviation for each group) [112] .
The methodology used for the generation of randomization sequence and the allocation concealment, as well as the blinding method, needs to be adequate and clearly described. Although some studies have chosen to randomize by lesions, typically for topical interventions, it may have made more clinical sense to randomize participants, especially in nonblinded trials.
The development of successful approaches for improving wound healing will lead to a reduced risk of developing scars in some lesions of CL and is likely to be a priority in the future. The investigation of specialized treatment strategies using patient satisfaction outcomes would be invaluable in future RCTs. The current evidence for different types of clinical management of Old World CL and for species such as L. tropica and L. aethiopica is lacking and emphasizes the need for more research. In American CL, clinical research on Leishmania braziliensis and Leishmania panamensis are the highest priority, because both species lead to the mucocutaneous form.
Reporting of Clinical Trials
Adequate reporting of RCTs improves transparency and enables the interpretation and replication of studies. Many journals require that trials conform to the guidelines in the Consolidated Standards of Reporting Trials (CONSORT) statement [113] . However, it is also important to ask for rigorous peer-review checks in journals.
Studies with more positive effects are more likely to be published than those with less conclusive results that normally remain unpublished, either because authors fail to write manuscripts and submit them to journals or because they are written in languages other than English [114] . Seemingly, the first study to be published on a particular intervention is more likely to show positive results. However, it is unethical to not publish RCTs with negative results. Fortunately, RCTs are currently registered in public databases, and unpublished studies can be easily detected.
CONCLUSIONS
A more evidence-based strategic approach based on the findings of 2 Cochrane systematic reviews of RCTs assessing treatments for CL may help to plan and prioritize global treatment recommendations and clinical research. There is much scope for improving the design and reporting of RCTs, and they can be improved by adopting general guidelines and rigorous peerreview checks in journals. There are other identified factors that have a particular effect on the validity of these trials, most notably the parasitological confirmation and determination of the causative Leishmania species, the use of longer duration designs, and clinically understandable and patient-orientated outcome measures.
Hopefully, the recommendations in this report will help in the process of overcoming the methodological challenges of RCTs investigating treatments for CL. We are aiming to create a World Health Organization CL clinical trials network with clinicians, health services, researchers, and patients throughout all affected countries. This concentration of resources may assist with the conduction of high-quality, multicenter RCTs that answer questions of importance to clinicians and patients.
